UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): March 17, 2008
Ardea Biosciences, Inc.
(Exact name of registrant as specified in its charter)
| |
|
|
|
|
| Delaware
|
|
1-33734
|
|
94-3200380 |
| |
|
|
|
|
(State or other jurisdiction
of incorporation)
|
|
(Commission
File Number)
|
|
(IRS Employer
Identification No.) |
| |
|
|
4939 Directors Place
San Diego, California
|
|
92121
(Zip Code) |
| (Address of principal executive
offices) |
|
|
Registrant’s telephone number, including area code:
(858) 652-6500
2131 Palomar Airport Road, Suite 300
Carlsbad, California
(Former name or former address, if changed since last report.)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the
filing obligation of the registrant under any of the following provisions:
|
|
|
| o |
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
|
|
| o |
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
|
|
| o |
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
|
|
| o |
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
TABLE OF CONTENTS
Item 2.02. Results of Operations and Financial Condition.
In the presentation referenced in Item 7 below, the Company disclosed that it ended fiscal year
2007 with approximately $66.2 million in cash. Additionally, the Company reported that it expects
to use $45 – $50 million to fund its operations in fiscal year 2008.
The information contained in this Item shall not be deemed “filed” for purposes of Section 18 of
the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or incorporated by reference
in any filing under the Securities Act of 1933, as amended (the “Securities Act”), or the Exchange
Act, except as shall be expressly set forth by specific reference in such a filing.
|
|
|
| Item 7.01. |
|
Regulation FD Disclosure |
The Company intends to present at conferences and conduct meetings with investors, stockholders and
analysts on or after March 18, 2008. A copy of the presentation materials to be used at those
conferences and meetings and from time to time thereafter is filed as Exhibit 99.1 hereto. The
Company does not intend to file any update of these presentation materials. The fact that these
presentation materials are being furnished should not be deemed an admission as to the materiality
of any information contained in the materials.
The Company has recently received certain clinical data related to its products and has announced a
conference call on March 18, 2008 to discuss such data with investors, stockholders and analysts.
A copy of the related press release is filed as Exhibit 99.2 to this Form 8-K and is incorporated
herein by reference in its entirety.
The information in this Item 7.01 and Exhibits 99.1 and 99.2 attached hereto shall not be deemed
“filed” for purposes of Section 18 of the Securities Exchange Act of 1934, nor shall such
information be deemed incorporated by reference in any filing under the Securities Act of 1933,
except as shall be expressly set forth by specific reference in such filing.
|
|
|
| Item 9.01. |
|
Financial Statements and Exhibits. |
(d) Exhibits. The following material is filed as an exhibit to this Current Report on Form 8-K:
| |
|
|
| Exhibit Number |
|
Document Description |
| 99.1
|
|
Ardea Biosciences, Inc. investor presentation
materials to be used at conferences and meetings
with investors, stockholders and analysts
beginning on or after March 18, 2008, and to be
used from time to time thereafter. |
|
|
|
|
|
| 99.2
|
|
Press Release, dated March 17, 2008. |